CSF3 and Thrombocytopenia: Haematologic toxicities (Table 2) consisted primarily of grade 3/4 neutropenia in 55% (32.5% grade 4) of patients despite prophylactic G-CSF administration, while grade 3/4 thrombocytopenia was encountered in 22.5% (7.5% grade 4) of patients.